Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shows promise in cutting COPD attacks for smokers

NCT ID NCT04751487

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called itepekimab in over 1,200 people with moderate-to-severe COPD who were either former or current smokers. The goal was to see if it could reduce the number of serious flare-ups and improve lung function compared to a placebo. The drug works by blocking a protein involved in inflammation, aiming to better control the disease rather than cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,239 people

The number who actually took part.

Started

Feb 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Participant must be 40 to 85 years of age inclusive. * Physician diagnosis of COPD for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition). * Smoking history of ≥10 pack-years: * For former smokers: participants who report that they are not currently smoking and smoking cessation must have occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently. * For current smokers: participants who report that they are currently smoking tobacco (participant smoked at least 1 cigarette per day on average during the past 7 days) at Screening (Visit 1A) and who are not currently participating in or planning to initiate a smoking cessation intervention at Screening (Visit 1A) or during Screening period. * Participants with moderate-to-severe COPD * Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to Screening in a participant in whom other causes of chronic cough \[eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis\] has been excluded). * Documented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic corticosteroids. At least one exacerbation must have occurred while participants were on their current controller therapy: * Moderate exacerbations will be recorded by the Investigator and are defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics. * Severe exacerbations will be recorded by the Investigator and are defined as AECOPD that require hospitalization or observation for \>24 hours in emergency department/urgent care facility. * Participants with standard of care controller therapy, for ≥3 months prior to Screening (Visit 1A) and at a stable dose of controller therapy for at least 1 month prior to the Screening, including either: inhaled corticosteroid (ICS) + long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) + LABA or LAMA + LABA + ICS. * Body mass index (BMI) ≥18.0 kg/m\^2, or BMI ≥16.0 kg/m\^2 for participants enrolled in East-Asian countries. * Female participant is not pregnant, not breastfeeding, and at least one of the following conditions applies: * not a women of child-bearing potential (WOCBP) OR * a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. - Exclusion criteria: * Current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines, or documented history of asthma unless asthma resolved before 18 years of age and has not recurred. * For former smokers: Active smoking or vaping of any products (eg, nicotine, tetrahydrocannabinol \[THC\]) within 6 months prior to Screening (Visit 1A). * For current smokers: vaping of any products (eg, nicotine, THC) within 6 months prior to Screening (Visit 1A). * Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening (Visit 1A) that may affect the participant's participation in the study. * Clinically significant and current pulmonary disease other than COPD, eg, sarcoidosis, interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α-1 anti-trypsin deficiency, or another diagnosed pulmonary disease. * Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe pulmonary hypertension. * Hypercapnia requiring bilevel positive airway pressure (BiPAP). * Moderate or severe exacerbation of COPD (AECOPD) within 4 weeks prior to Screening (Visit 1A). * Prior history of / planned: lung pneumonectomy for any reason, or lung volume reduction procedures (including bronchoscopic volume reduction) for COPD. Note: Surgical biopsy, or segmentectomy, or wedge resection, or lobectomy for other diseases would not be excluded. * Unstable ischemic heart disease, including acute myocardial infarction within the past 1 year prior to Screening, or unstable angina in the 6 months prior to Screening (Visit 1A). * Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation. * Uncontrolled hypertension (ie, systolic blood pressure \[BP\] \>180 mm Hg or diastolic BP \>110 mm Hg with or without use of anti-hypertensive therapy). * Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A). * History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Screening (Visit 1A). * Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who have not yet sufficiently recovered to participate in the procedures of a clinical trial. * Evidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that may not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment). * Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis. * History of malignancy within 5 years before Screening (Visit 1A), except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin. * Previous use of itepekimab. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • AES Salt Lake City- Site Number : 8400332

    Murray, Utah, 84123, United States

  • Advanced Pulmonary Research Institute Site Number : 8400018

    Loxahatchee Groves, Florida, 33470, United States

  • Advanced Respiratory and Sleep Medicine- Site Number : 8400022

    Huntersville, North Carolina, 28078, United States

  • Allegheny Health Network- Site Number : 8400058

    Pittsburgh, Pennsylvania, 15212, United States

  • Allianz Research Institute Colorado Site Number : 8400061

    Denver, Colorado, 80219, United States

  • American Health Research- Site Number : 8400002

    Charlotte, North Carolina, 28277, United States

  • Aurora BayCare Medical Center Site Number : 8400046

    Green Bay, Wisconsin, 54311, United States

  • BRCR Medical Center Site Number : 8400180

    San Juan, 00907, Puerto Rico

  • BRCR Medical Center, Inc. Site Number : 8400190

    Ponce, 00717-1322, Puerto Rico

  • Beautiful Minds Clinical Research Center Site Number : 8400352

    Cutler Bay, Florida, 33157, United States

  • CECAP - Centro de Cardiologia Clinica e Pesquisa Dra. Juliana Souza- Site Number : 0760018

    Brasília, Federal District, 70710-100, Brazil

  • CEDOES - Centro de Diagnostico e Pesquisa de Osteoporose do ES- Site Number : 0760009

    Vitória, Espírito Santo, 29055 450, Brazil

  • CEMEC - Centro Multidisciplinar de Estudos Clinicos- Site Number : 0760015

    São Bernardo do Campo, São Paulo, 09715-090, Brazil

  • CEPIC - Centro Paulista de Investigação Clínica- Site Number : 0760004

    São Paulo, 04266-010, Brazil

  • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760012

    Curitiba, Paraná, 80060-240, Brazil

  • Captain James A. Lovell Federal Health Care Center Site Number : 8400032

    North Chicago, Illinois, 60064, United States

  • Cardiopulmonary Research- Site Number : 8400040

    Guaynabo, 00968, Puerto Rico

  • Care Access Fairview Heights Site Number : 8400033

    Fairview Heights, Illinois, 62208, United States

  • Care Access Site Number : 8400276

    Boston, Massachusetts, 02110, United States

  • Care Access Site Number : 8400281

    Boston, Massachusetts, 02110, United States

  • Central Florida Pulmonary Group, PA- Site Number : 8400192

    Orlando, Florida, 32803, United States

  • Clincove: Plano Primary Care Clinic Site Number : 8400424

    Plano, Texas, 75024, United States

  • Clinica de Alergia Martti Antila Site Number : 0760008

    Sorocaba, São Paulo, 18040-425, Brazil

  • Clinical Research of West Florida, Inc- Site Number : 8400008

    Tampa, Florida, 33606, United States

  • Clinical Trials Center of Middle Tennessee Site Number : 8400025

    Franklin, Tennessee, 37067, United States

  • Columbus Clinical Services- Site Number : 8400054

    Miami, Florida, 33125, United States

  • Cotton O'Neil Garfield- Site Number : 8400063

    Topeka, Kansas, 66606, United States

  • Direct Helpers Medical Center Inc- Site Number : 8400065

    Hialeah, Florida, 33012, United States

  • Faculdade de Medicina da Universidade Estadual Paulista- Site Number : 0760005

    Botucatu, São Paulo, 18618-687, Brazil

  • Finlay Medical Research Site Number : 8400007

    Miami, Florida, 33126, United States

  • Finlay Medical Research- Site Number : 8400011

    Greenacres City, Florida, 33467, United States

  • Genesis Clinical Research, LLC Site Number : 8400182

    Tampa, Florida, 33603, United States

  • Helix Biomedics, LLC - Site Number : 8400049

    Boynton Beach, Florida, 33435, United States

  • Henry Ford Hospital Site Number : 8400052

    Detroit, Michigan, 48202, United States

  • Heuer M.D. Research Site Number : 8400016

    Orlando, Florida, 32819, United States

  • Hospital Nossa Senhora da Conceicao - Grupo Hospitalar Conceicao- Site Number : 0760006

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Sao Domingos- Site Number : 0760016

    São Luís, Maranhão, 65060-645, Brazil

  • Hospital Sao Lucas da PUCRS- Site Number : 0760007

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Illinois Lung Institute- Site Number : 8400024

    Peoria, Illinois, 61605, United States

  • Innovation Medical Research Center- Site Number : 8400067

    Palmetto Bay, Florida, 33157, United States

  • Innovative Research of West Florida, Inc- Site Number : 8400041

    Clearwater, Florida, 33756, United States

  • Inspire Pulmonary & Sleep Medicine Specialists Site Number : 8400232

    Temecula, 92590, Puerto Rico

  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A Site Number : 0760017

    Rio de Janeiro, 20241-180, Brazil

  • Instituto Ceos Site Number : 0760021

    Porto Alegre, Rio Grande do Sul, 90480-020, Brazil

  • Investigational Site Number : 0320001

    CABA, Buenos Aires, C1414AIF, Argentina

  • Investigational Site Number : 0320002

    Vicente Lopez, Buenos Aires F.D., B1602DQD, Argentina

  • Investigational Site Number : 0320003

    Rosario, Santa Fe Province, S2000DBS, Argentina

  • Investigational Site Number : 0320004

    Rosario, Santa Fe Province, S2000JKR, Argentina

  • Investigational Site Number : 0320005

    Pergamino, Buenos Aires, B2700CPM, Argentina

  • Investigational Site Number : 0320006

    Buenos Aires, Buenos Aires F.D., 1060, Argentina

  • Investigational Site Number : 0320007

    Rosario, Santa Fe Province, 2000, Argentina

  • Investigational Site Number : 0320008

    CABA, Buenos Aires, C1023AAB, Argentina

  • Investigational Site Number : 0320009

    Berazategui, Buenos Aires, CP 1884, Argentina

  • Investigational Site Number : 1000001

    Sofia, 1142, Bulgaria

  • Investigational Site Number : 1000002

    Plovdiv, 4002, Bulgaria

  • Investigational Site Number : 1000003

    Rousse, 7002, Bulgaria

  • Investigational Site Number : 1000004

    Gabrovo, 5300, Bulgaria

  • Investigational Site Number : 1000005

    Montana, 3403, Bulgaria

  • Investigational Site Number : 1000006

    Sofia, 1680, Bulgaria

  • Investigational Site Number : 1000008

    Blagoevgrad, 2700, Bulgaria

  • Investigational Site Number : 1000009

    Haskovo, 6305, Bulgaria

  • Investigational Site Number : 1000012

    Rousse, 7000, Bulgaria

  • Investigational Site Number : 1000013

    Dupnitsa, 2600, Bulgaria

  • Investigational Site Number : 1240001

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • Investigational Site Number : 1240002

    Victoriaville, Quebec, G6P 3Z8, Canada

  • Investigational Site Number : 1240003

    Québec, G1N 4V3, Canada

  • Investigational Site Number : 1240004

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Investigational Site Number : 1240005

    St-charles Borrommee, Quebec, J6E 2B4, Canada

  • Investigational Site Number : 1240006

    Sherwood Park, Alberta, T8H 0N2, Canada

  • Investigational Site Number : 1240009

    Toronto, Ontario, M5T 3A9, Canada

  • Investigational Site Number : 1240012

    Moncton, New Brunswick, E1C2Z3, Canada

  • Investigational Site Number : 1240014

    Kelowna, British Columbia, V1Y 4N7, Canada

  • Investigational Site Number : 1240016

    Penticton, British Columbia, V2A 5L5, Canada

  • Investigational Site Number : 1240018

    Windsor, Ontario, N8X 5A6, Canada

  • Investigational Site Number : 1240019

    Terrebonne, Quebec, J6V 2H2, Canada

  • Investigational Site Number : 1240020

    Burlington, Ontario, L7N 3V2, Canada

  • Investigational Site Number : 1240021

    Ajax, Ontario, L1S 2J5, Canada

  • Investigational Site Number : 1240022

    Windsor, Ontario, N8X 1T3, Canada

  • Investigational Site Number : 1240023

    Guelph, Ontario, N1H 6J2, Canada

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 7500692, Chile

  • Investigational Site Number : 1520002

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, 7500698, Chile

  • Investigational Site Number : 1520005

    Santiago, Reg Metropolitana de Santiago, 8910131, Chile

  • Investigational Site Number : 1520006

    Quillota, Valparaiso, 2260877, Chile

  • Investigational Site Number : 1520007

    Santiago, Reg Metropolitana de Santiago, 7500010, Chile

  • Investigational Site Number : 1520008

    Santiago, Reg Metropolitana de Santiago, 7500587, Chile

  • Investigational Site Number : 1520009

    Valdivia, Los Ríos Region, 5110683, Chile

  • Investigational Site Number : 2030001

    Jindrichuv Hradec III, 37701, Czechia

  • Investigational Site Number : 2030002

    Prague, 140 46, Czechia

  • Investigational Site Number : 2030004

    Ostrava, 70800, Czechia

  • Investigational Site Number : 2030005

    Mladá Boleslav, 29301, Czechia

  • Investigational Site Number : 2030006

    Teplice, 415 01, Czechia

  • Investigational Site Number : 2030007

    Varnsdorf, 40747, Czechia

  • Investigational Site Number : 2030008

    Olomouc, 779 00, Czechia

  • Investigational Site Number : 2030009

    Měšice, 250 64, Czechia

  • Investigational Site Number : 2080001

    Hvidovre, 2650, Denmark

  • Investigational Site Number : 2080003

    Vejle, 7100, Denmark

  • Investigational Site Number : 2330001

    Tartu, 50406, Estonia

  • Investigational Site Number : 2500001

    Lyon, 69004, France

  • Investigational Site Number : 2500002

    Montpellier, France

  • Investigational Site Number : 2500003

    Pessac, 33600, France

  • Investigational Site Number : 2500004

    Reims, 51090, France

  • Investigational Site Number : 2680001

    Tbilisi, 0160, Georgia

  • Investigational Site Number : 2680002

    Tbilisi, 0168, Georgia

  • Investigational Site Number : 2680003

    Batumi, 6010, Georgia

  • Investigational Site Number : 2760001

    Mainz, 55128, Germany

  • Investigational Site Number : 2760002

    Hamburg, 20354, Germany

  • Investigational Site Number : 2760003

    Lübeck, 23552, Germany

  • Investigational Site Number : 2760004

    Berlin, 10787, Germany

  • Investigational Site Number : 2760005

    Frankfurt am Main, 60596, Germany

  • Investigational Site Number : 2760006

    Bendorf, 56068, Germany

  • Investigational Site Number : 2760007

    Leipzig, 04347, Germany

  • Investigational Site Number : 2760008

    Leipzig, 04299, Germany

  • Investigational Site Number : 2760009

    Berlin, 10961, Germany

  • Investigational Site Number : 2760010

    Berlin, 12159, Germany

  • Investigational Site Number : 2760011

    Rosenheim, 83022, Germany

  • Investigational Site Number : 2760012

    Neu-Isenburg, 63263, Germany

  • Investigational Site Number : 2760014

    Hanover, 30625, Germany

  • Investigational Site Number : 3480001

    Százhalombatta, 2440, Hungary

  • Investigational Site Number : 3480002

    Balassagyarmat, 2660, Hungary

  • Investigational Site Number : 3480003

    Püspökladány, 4150, Hungary

  • Investigational Site Number : 3480004

    Hajdunánás, 4080, Hungary

  • Investigational Site Number : 3480005

    Edelény, 3780, Hungary

  • Investigational Site Number : 3480009

    Budapest, 1106, Hungary

  • Investigational Site Number : 3480012

    Szombathely, 9700, Hungary

  • Investigational Site Number : 3560001

    Chandigarh, 160012, India

  • Investigational Site Number : 3560005

    Nagpur, 440015, India

  • Investigational Site Number : 3560009

    Nashik, 422007, India

  • Investigational Site Number : 3560010

    Kolkata, 700107, India

  • Investigational Site Number : 3560012

    Pune, 411004, India

  • Investigational Site Number : 3560013

    Jaipur, 302023, India

  • Investigational Site Number : 3560014

    India, 440010, India

  • Investigational Site Number : 3560016

    Belagavi, 590010, India

  • Investigational Site Number : 3560017

    Nagpur, 440012, India

  • Investigational Site Number : 3560018

    Pune, 411057, India

  • Investigational Site Number : 3560019

    Kanpur, 208002, India

  • Investigational Site Number : 3760001

    Petah Tikva, 49100, Israel

  • Investigational Site Number : 3760002

    Jerusalem, 91120, Israel

  • Investigational Site Number : 3760003

    Jerusalem, 91031, Israel

  • Investigational Site Number : 3760004

    Rehovot, 76100, Israel

  • Investigational Site Number : 3760009

    Ramat Gan, 5266202, Israel

  • Investigational Site Number : 3920003

    Osaka, Osaka, 530-8480, Japan

  • Investigational Site Number : 3920005

    Fukuoka, Fukuoka, 815-0032, Japan

  • Investigational Site Number : 3920006

    Yao-shi, Osaka, 581-0011, Japan

  • Investigational Site Number : 3920007

    Sakai-shi, Osaka, 591-8555, Japan

  • Investigational Site Number : 3920009

    Sakaide-shi, Kagawa-ken, 762-8550, Japan

  • Investigational Site Number : 3920010

    Hiroshima, Hiroshima, 734-8530, Japan

  • Investigational Site Number : 3920011

    Konan-ku, Yokohama-shi, Kanagawa, 234-0054, Japan

  • Investigational Site Number : 3920013

    Himeji-shi, Hyōgo, 670-0849, Japan

  • Investigational Site Number : 3920014

    Takamatsu, Kagawa-ken, 761-8073, Japan

  • Investigational Site Number : 3920015

    Mizunami-shi, Gifu, 509-6134, Japan

  • Investigational Site Number : 3920016

    Shinagawa-ku, Tokyo, 140-8522, Japan

  • Investigational Site Number : 3920017

    Chuo-ku, Tokyo, 104-0031, Japan

  • Investigational Site Number : 3920019

    Itabashi-ku, Tokyo, 173-8610, Japan

  • Investigational Site Number : 3920020

    Nagoya, Aichi-ken, 457-8511, Japan

  • Investigational Site Number : 3920021

    Kure-shi, Hiroshima, 737-0193, Japan

  • Investigational Site Number : 3920023

    Nagoya, Aichi-ken, 455-8530, Japan

  • Investigational Site Number : 3920024

    Chuo-ku, Tokyo, 104-0031, Japan

  • Investigational Site Number : 3920025

    Shibuya-ku, Tokyo, 150-8935, Japan

  • Investigational Site Number : 3920026

    Osaka, Osaka, 545-8586, Japan

  • Investigational Site Number : 3920027

    Fukuoka, Fukuoka, 819-8555, Japan

  • Investigational Site Number : 3920029

    Kiyose, Tokyo, 204-8522, Japan

  • Investigational Site Number : 3920030

    Kurume-shi, Fukuoka, 830-0011, Japan

  • Investigational Site Number : 3920035

    Kure-shi, Hiroshima, 737-8505, Japan

  • Investigational Site Number : 3920036

    Sano-shi, Tochigi, 327-8511, Japan

  • Investigational Site Number : 3920037

    Shinagawa-ku, Tokyo, 142-8666, Japan

  • Investigational Site Number : 3920038

    Sapporo, Hokkaido, 006-8555, Japan

  • Investigational Site Number : 3920039

    Yokohama, Kanagawa, 223-0059, Japan

  • Investigational Site Number : 3920040

    Chuo-ku, Tokyo, 103-0022, Japan

  • Investigational Site Number : 3920041

    Toshima-ku, Tokyo, 170-0003, Japan

  • Investigational Site Number : 3920042

    Sapporo, Hokkaido, 064-0804, Japan

  • Investigational Site Number : 3920043

    Matsusaka-shi, Mie-ken, 515-8544, Japan

  • Investigational Site Number : 4100001

    Seoul, 06591, South Korea

  • Investigational Site Number : 4100002

    Wŏnju, Gangwon-do, 26426, South Korea

  • Investigational Site Number : 4100003

    Incheon, Incheon-gwangyeoksi, 21431, South Korea

  • Investigational Site Number : 4100004

    Seoul, Seoul-teukbyeolsi, 05030, South Korea

  • Investigational Site Number : 4100005

    Seongnam-si, Gyeonggi-do, 463-707, South Korea

  • Investigational Site Number : 4280001

    Riga, LV-1002, Latvia

  • Investigational Site Number : 4280002

    Daugavpils, LV-5417, Latvia

  • Investigational Site Number : 4400001

    Kaunas, 50161, Lithuania

  • Investigational Site Number : 4400002

    Kaunas, 49449, Lithuania

  • Investigational Site Number : 4400003

    Klaipėda, 92231, Lithuania

  • Investigational Site Number : 4840001

    Monterrey, Nuevo León, 64460, Mexico

  • Investigational Site Number : 4840002

    Monterrey, Nuevo León, 66465, Mexico

  • Investigational Site Number : 4840003

    Chihuahua City, 31000, Mexico

  • Investigational Site Number : 4840004

    Veracruz, 91910, Mexico

  • Investigational Site Number : 4840006

    Mexico City, 14050, Mexico

  • Investigational Site Number : 4840007

    Durango, 34000, Mexico

  • Investigational Site Number : 4840008

    Monterrey, Nuevo León, 64710, Mexico

  • Investigational Site Number : 4840009

    Monterrey, Nuevo León, 64718, Mexico

  • Investigational Site Number : 4840010

    Aguascalientes, 20230, Mexico

  • Investigational Site Number : 4840012

    Durango, Durango, 34080, Mexico

  • Investigational Site Number : 5280001

    Breda, 4818 CK, Netherlands

  • Investigational Site Number : 5280005

    Arnhem, 6815 AD, Netherlands

  • Investigational Site Number : 5280008

    Zutphen, 7207 AE, Netherlands

  • Investigational Site Number : 5780001

    Lørenskog, 1478, Norway

  • Investigational Site Number : 6160002

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Investigational Site Number : 6160003

    Malbork, Pomeranian Voivodeship, 82-200, Poland

  • Investigational Site Number : 6160005

    Wołomin, Masovian Voivodeship, 05-200, Poland

  • Investigational Site Number : 6160008

    Bialystok, Podlaskie Voivodeship, 15-044, Poland

  • Investigational Site Number : 6160009

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Investigational Site Number : 6200001

    Guimarães, 4810-061, Portugal

  • Investigational Site Number : 6200002

    Braga, 4710-243, Portugal

  • Investigational Site Number : 6200006

    Aveiro, 3810-501, Portugal

  • Investigational Site Number : 6200009

    Almada, 2801-951, Portugal

  • Investigational Site Number : 6200010

    Matosinhos Municipality, 4464-513, Portugal

  • Investigational Site Number : 6430001

    Moscow, 115093, Russia

  • Investigational Site Number : 6430002

    Moscow, 105077, Russia

  • Investigational Site Number : 6430003

    Saint Petersburg, 194354, Russia

  • Investigational Site Number : 6430004

    Saint Petersburg, 193231, Russia

  • Investigational Site Number : 6430005

    Moscow, 115280, Russia

  • Investigational Site Number : 6430006

    Ulyanovsk, 432017, Russia

  • Investigational Site Number : 7100002

    Cape Town, 7530, South Africa

  • Investigational Site Number : 7100003

    Parow, 7500, South Africa

  • Investigational Site Number : 7100004

    Gatesville, 7764, South Africa

  • Investigational Site Number : 7100005

    Durban, 4001, South Africa

  • Investigational Site Number : 7100006

    Durban, 4071, South Africa

  • Investigational Site Number : 7100009

    Pretoria, 0145, South Africa

  • Investigational Site Number : 7100012

    Middelburg, 1055, South Africa

  • Investigational Site Number : 7100013

    Benoni, 1500, South Africa

  • Investigational Site Number : 7100015

    Chatsworth, 4091, South Africa

  • Investigational Site Number : 7100016

    Durban, 4302, South Africa

  • Investigational Site Number : 7100017

    Durban, 4001, South Africa

  • Investigational Site Number : 7100019

    Cape Town, 7130, South Africa

  • Investigational Site Number : 7240001

    Málaga, 29010, Spain

  • Investigational Site Number : 7240002

    Mérida / Badajoz, Extremadura, 06800, Spain

  • Investigational Site Number : 7240003

    Madrid, 28007, Spain

  • Investigational Site Number : 7240004

    Palma de Mallorca, Balears [Baleares], 07120, Spain

  • Investigational Site Number : 7240006

    Sant Boi de Llobregat, Barcelona [Barcelona], 08830, Spain

  • Investigational Site Number : 7240007

    Madrid / Madrid, Madrid, Comunidad de, 28040, Spain

  • Investigational Site Number : 7240008

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Investigational Site Number : 7240009

    Lleida / Lleida, Lleida [Lérida], 25198, Spain

  • Investigational Site Number : 7240010

    Cáceres, 10003, Spain

  • Investigational Site Number : 7240012

    Zaragoza, 50009, Spain

  • Investigational Site Number : 7240013

    Santander, Cantabria, 39008, Spain

  • Investigational Site Number : 7240014

    Barcelona, Barcelona [Barcelona], 08017, Spain

  • Investigational Site Number : 7920001

    Istanbul, 34303, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Mersin, 33343, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Izmir, 35040, Turkey (Türkiye)

  • Investigational Site Number : 7920005

    Balcali Adana, 01330, Turkey (Türkiye)

  • Investigational Site Number : 7920006

    Kirikkale, 71450, Turkey (Türkiye)

  • Investigational Site Number : 7920007

    Ankara, 06100, Turkey (Türkiye)

  • Investigational Site Number : 8260001

    Newcastle upon Tyne, NE4 6BE, United Kingdom

  • Investigational Site Number : 8260002

    Chertsey, Surrey, KT16 0PZ, United Kingdom

  • Investigational Site Number : 8260003

    Bradford, BD9 6RJ, United Kingdom

  • Investigational Site Number : 8260005

    Liverpool, L143PE, United Kingdom

  • Investigational Site Number : 8260006

    Wishaw, Glasgow City, ML2 0DP, United Kingdom

  • Investigational Site Number : 8260007

    Tyne and Wear, North Tyneside, NE29 8NH, United Kingdom

  • Investigational Site Number : 8260008

    Milton Keynes, MK15 0DU, United Kingdom

  • Irmandade da Santa Casa de Misericordia de Porto Alegre- Site Number : 0760001

    Porto Alegre, Rio Grande do Sul, 90020-090, Brazil

  • Johns Hopkins Asthma and Allergy Center- Site Number : 8400055

    Baltimore, Maryland, 21224, United States

  • Kaiser Permanente Center for Health Research Site Number : 8400039

    Portland, Oregon, 97227, United States

  • Lexington VA Health Care System- Site Number : 8400036

    Lexington, Kentucky, 40502, United States

  • Lowcountry Lung & Critical Care- Site Number : 8400175

    Charleston, South Carolina, 29406, United States

  • MCR Research Site Number : 8400425

    Miami, Florida, 33126, United States

  • Medster Research, LLC Site Number : 8400051

    Valdosta, Georgia, 31605, United States

  • Medtrial, LLC Site Number : 8400048

    Columbia, South Carolina, 29204, United States

  • Multi-Specialty Research Associates, Inc- Site Number : 8400044

    Lake City, Florida, 32055, United States

  • My Community Research Center Site Number : 8400060

    Miami, Florida, 33155, United States

  • New York - Presbyterian Queens- Site Number : 8400028

    Flushing, New York, 11355, United States

  • North Florida/South Georgia Veterans Health System Site Number : 8400176

    Gainesville, Florida, 32608, United States

  • North Georgia Clinical Research Site Number : 8400013

    Woodstock, Georgia, 30189, United States

  • Nucleo de Pesquisa Clinica e Ensino da Rede Sao Camilo- Site Number : 0760013

    São Paulo, São Paulo, 04014-002, Brazil

  • OK Clinical Research LLC- Site Number : 8400001

    Edmond, Oklahoma, 73034, United States

  • Omega Research - Site Number : 8400031

    DeBary, Florida, 32713, United States

  • Oviedo Medical Research Site Number : 8400026

    Oviedo, Florida, 32765, United States

  • PUC Campinas - Sociedade Campineira de Educaçao e Instruçao- Site Number : 0760010

    Campinas, São Paulo, 13059-900, Brazil

  • Palmtree Clinical Research Site Number : 8400184

    Palm Springs, California, 92262, United States

  • Phoenix Medical Research- Site Number : 8400019

    Miami, Florida, 33165, United States

  • Pines Care Research Center LLC- Site Number : 8400056

    Pembroke Pines, Florida, 33025, United States

  • Pulmonary & Critical Care Site Number : 8400047

    Shreveport, Louisiana, 71105, United States

  • Radiance Clinical Research- Site Number : 8400037

    Lampasas, Texas, 76550-1820, United States

  • Remington-Davis Inc- Site Number : 8400004

    Columbus, Ohio, 43215, United States

  • Renstar Medical Research- Site Number : 8400015

    Ocala, Florida, 34470, United States

  • Revive Research Institute Site Number : 8400186

    Lathrup Village, Michigan, 48076, United States

  • SER da Bahia- Site Number : 0760020

    Salvador, Estado de Bahia, 40150-150, Brazil

  • Santa Casa de Belo Horizonte - Hospital Emygdio Germano- Site Number : 0760014

    Belo Horizonte, Minas Gerais, 30150-221, Brazil

  • Sarasota Memorial Health Care System Clinical ResearchCenter- Site Number : 8400178

    Sarasota, Florida, 34239, United States

  • Schenectady Pulmonary and Critical Care Associates- Site Number : 8400029

    Schenectady, New York, 12308, United States

  • Sciences Connections, LLC Site Number : 8400045

    Doral, Florida, 33178, United States

  • Sierra Clinical Research- Site Number : 8400005

    Las Vegas, Nevada, 89106, United States

  • Smart Medical Research Site Number : 8400191

    Brooklyn, New York, 11230, United States

  • St. Luke's University Health Network- Site Number : 8400187

    Bethlehem, Pennsylvania, 18015, United States

  • Sun Research Institute - Site Number : 8400183

    San Antonio, Texas, 78215, United States

  • Synexus Phoenix Central (Central Phoenix Medical Clinic)- Site Number : 8400333

    Phoenix, Arizona, 85020, United States

  • TTS Research- Site Number : 8400012

    Boerne, Texas, 78006, United States

  • Temple University Hospital Site Number : 8400062

    Philadelphia, Pennsylvania, 19140-5103, United States

  • The Iowa Clinic Site Number : 8400034

    West Des Moines, Iowa, 50266, United States

  • The Rheumatology and Pulmonary Clinic- Site Number : 8400053

    Beckley, West Virginia, 25801, United States

  • Toledo Institute of Clinical Research- Site Number : 8400014

    Toledo, Ohio, 43617, United States

  • UCSF Fresno - Site Number : 8400030

    Fresno, California, 93701, United States

  • United Memorial Medical Center (UMMC)- Site Number : 8400193

    Houston, Texas, 77091, United States

  • University of Cincinnati- Site Number : 8400042

    Cincinnati, Ohio, 45267, United States

  • VA Western New York Healthcare System Site Number : 8400050

    Buffalo, New York, 14215, United States

  • VitaLink Research- Gaffney- Site Number : 8400003

    Gaffney, South Carolina, 29340, United States

  • Washington University School of Medicine- Site Number : 8400035

    St Louis, Missouri, 63110, United States

  • Y and L Advance Health Care, Inc D/B/A Elite Clinical Res- Site Number : 8400009

    Miami, Florida, 33144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.